Portland, Ore. (December 11, 2017)— The Corrona® Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, the leading sponsor of registries in autoimmune and immune-mediated diseases, announces it has expanded into Canada and has enrolled its first Canadian psoriasis patient.
With this expansion, the new Canadian sites and patients join a U.S. network of more than 230 participating dermatology health care providers and 3,700 patients already participating in the Corrona® Psoriasis Registry.
“We very much look forward to working with Canadian dermatologists and their patients. We anticipate that differences in the U.S. and Canadian healthcare systems will lead to novel insights relating to prescribing patterns and clinical outcomes,” said Dr. Jeff Greenberg, chief scientific officer of Corrona.
Launched in 2015, the psoriasis registry has contributed data to multiple research posters, which have been presented at medical conferences around the world. Most recently, Corrona® Psoriasis Registry data was included in a research article with an accompanying commentary in the Journal of the American Academy of Dermatology.
“We’re excited to join the registry and contribute to the growing data collected on safety and effectiveness outcomes,” said Dr. Wayne Gulliver, Newlab Clinical Research and professor of Medicine and Dermatology, Memorial University of Newfoundland.
The Corrona® Psoriasis Registry is the largest, independent registry of psoriasis patients. Created as a commitment to the psoriasis community, the registry’s goal is to help researchers compare the safety and effectiveness of approved psoriasis therapies.
To learn more about the Corrona® Psoriasis Registry and to get involved, visit https://www.corrona.org/registries/psoriasis.
About the National Psoriasis Foundation
Celebrating 50 years of patient support, advocacy, research funding, and education, the National Psoriasis Foundation (NPF) is the world’s leading nonprofit fighting for individuals with psoriasis and psoriatic arthritis. NPF is on a continued mission to drive efforts to cure psoriatic disease and dramatically improve the lives of more than 8 million Americans affected by this chronic immune mediated disease. As part of that effort, in 2016 the NPF created a Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. In addition, the NPF has funded more than $17 million in research grants and fellowships to date. Learn more at www.psoriasis.org.
Corrona was founded in 2001 by leading physicians dedicated to advancing and improving the care of patients with chronic autoimmune diseases. Its mission is to advance research and improve the quality of patient care through world-class observational cohorts. Corrona provides longitudinal clinical data, patient reported measures, and research results to biopharmaceutical companies. Corrona data analysis provides a rich framework in which to explore topics such as comparative effectiveness, post market safety reporting, and commercial applications.Read more at www.corrona.org